Skip to main content

Funding

11
Mar 2022

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.
02
Feb 2022

The Norwegian "New Method" framework is developing prioritization criteria for the evaluation of medical technologies and procedures

The "New Method" is currently developing criteria for which methods other than drugs shall be prioritized for assessment within the framework at the national or local levels. On January 17, 2022, the project status was presented at the Ordering Forum for "New Method." It was reported that the project would require more resources and time than initially thought.
05
Jan 2022

Theme survey for obstructive pulmonary diseases completed by Swedish TLV

In December 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) finished the theme survey in the obstructive pulmonary diseases field, which was conducted as a part of the Orderly Introduction for Medical Technologies framework. Identified technologies could potentially be included in the Orderly Introduction of Medical Technologies framework, which aims to facilitate the introduction of novel technologies on the national level.
15
Nov 2021

NHSX Adoption Fund awarded projects to improve digital pathways in England

In November 2021, NHSX announced projects to improve digital pathways awarded for funding from the newly created Adoption Fund. Funding opportunities will support Integrated Care Systems (ICSs) with initiatives to test out digital pathways across various specialty areas, including gastroenterology, musculoskeletal, and cardiology. A total of 35 applications were successful and will share funding of £6.5 million.
25
Oct 2021

NHSX announced Digital Health Partnership Award first phase winners

On September 29, 2021, NHSX announced the first phase winners of a Digital Health Partnership Award aimed to help NHS organizations receive funding to accelerate the adoption of digital health products and services to monitor patients with long-term conditions remotely. There will be three categories of funding: projects requiring the support of up to £100,000, £250,000, and £500,000.
07
Oct 2021

Budget for Med Tech evaluation significantly increased in Spain

On September 10, 2021, it was announced that the Government of Spain had increased the budget allocated to the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS) by 48.2% (compared to last year) for the development of the annual work plan. In total, the 2021 budget for the evaluation of health technologies in the National Health System amounts to €6,149,510. As a consequence of the budget increase, the RedETS 2021 Work Plan has included three new lines of evaluation.
24
Sep 2021

NHS is rolling out two types of testing (genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia)

In August 2021, NHS announced rolling out genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia. These decisions are made in line with the NHS Long Term Plan committed to increasing access to genomic testing, improving diabetes care across the country, and investing in cutting-edge technologies.